iShares Core MSCI EAFE ETF vs InMode Ltd — how do they compare? iShares Core MSCI EAFE ETF trades at $96.22 (market cap $189.19B), while InMode Ltd trades at $14.12 (market cap $809.93M). The key difference: iShares Core MSCI EAFE ETF is far larger — about 233.6× InMode Ltd's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and InMode Ltd for 29 Days on average.
| IEFA | INMD | |
|---|---|---|
Market Cap | $189.19B | $809.93M |
Volume | 8,441,787 | 365,490 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $16.62 |
52-Week Low | $85.06 | $12.76 |
Typical Hold Time | 41 Days | 29 Days |
Enterprise Value | — | $313.27M |
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with a bearish technical signal. The ETF manages $196 billion in assets, focusing on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors but lower recent performance than some peers. Technical indicators show oversold conditions with RSI at 28.63, while moving averages remain bearish with key support at $95.
The outlook remains cautious given bearish technical momentum and competitive pressure from lower-cost alternatives. International diversification benefits are offset by underperformance relative to global and emerging market ETFs. Key risks include currency fluctuations and concentrated U.S. market exposure driving defensive shifts.
INMD trades at $14.01, up 0.14% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 earnings of $0.35 per share, beating expectations, and maintains a strong gross profit margin of 76.52%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The outlook is mixed: valuation metrics like P/E of 11.63 and EV/EBITDA of 4.48 appear attractive, but declining net income and bearish technicals pose risks. Analyst consensus is divided with 45.45% buy ratings, highlighting potential upside from strategic developments against execution challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →